Loading company
Latest annual · FY2025
Millions- Total revenues
- 244
- Operating income
- 68
- Net income
- 87
- Free cash flow
- 106
Latest quarter · Q3 FY2026
Millions- Total revenues
- 40
- Operating income
- 13
- Net income
- 14
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2022 to FY2025
- n/m
- Revenue, 5 yearsFY2020 to FY2025
- n/m
- Net income, 5 yearsFY2020 to FY2025
- n/m
Keros Therapeutics, Inc. (KROS) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Revenue | $243.9 million | $0 | 10-K 2026-03-04 · proof | |
| Operating income | $67.6 million | -$210.8 million | 10-K 2026-03-04 · proof | |
| Net income | $87 million | -$187.4 million | 10-K 2026-03-04 · proof | |
| Cash from operating activities | $107.5 million | -$160.9 million | 10-K 2026-03-04 · proof | |
| Free cash flow | $106 million | -$162.8 million | 10-K 2026-03-04 · proof | |
| Total assets | $338 million | $615.9 million | -45.1% | 10-K 2026-03-04 · proof |
| Total liabilities | $34.9 million | $44.3 million | -21.3% | 10-K 2026-03-04 · proof |
| Cash and cash equivalents | $287.4 million | $559.9 million | -48.7% | 10-K 2026-03-04 · proof |
- What was Keros Therapeutics, Inc. (KROS)'s revenue in fiscal 2025?
- Keros Therapeutics, Inc. (KROS) reported revenue of $243.9 million for fiscal 2025 (the year ended Dec 31, 2025), against $0 the year before. Source: the 10-K filed with the SEC on Mar 4, 2026. SEC
- What was Keros Therapeutics, Inc. (KROS)'s operating income in fiscal 2025?
- Keros Therapeutics, Inc. (KROS) reported operating income of $67.6 million for fiscal 2025 (the year ended Dec 31, 2025), against -$210.8 million the year before. Source: the 10-K filed with the SEC on Mar 4, 2026. SEC
- What was Keros Therapeutics, Inc. (KROS)'s net income in fiscal 2025?
- Keros Therapeutics, Inc. (KROS) reported net income of $87 million for fiscal 2025 (the year ended Dec 31, 2025), against -$187.4 million the year before. Source: the 10-K filed with the SEC on Mar 4, 2026. SEC
- What was Keros Therapeutics, Inc. (KROS)'s cash from operating activities in fiscal 2025?
- Keros Therapeutics, Inc. (KROS) reported cash from operating activities of $107.5 million for fiscal 2025 (the year ended Dec 31, 2025), against -$160.9 million the year before. Source: the 10-K filed with the SEC on Mar 4, 2026. SEC
- What was Keros Therapeutics, Inc. (KROS)'s free cash flow in fiscal 2025?
- Keros Therapeutics, Inc. (KROS) reported free cash flow of $106 million for fiscal 2025 (the year ended Dec 31, 2025), against -$162.8 million the year before. Source: the 10-K filed with the SEC on Mar 4, 2026. SEC
- What are Keros Therapeutics, Inc. (KROS)'s total assets?
- As of Dec 31, 2025, Keros Therapeutics, Inc. (KROS) reported total assets of $338 million, against $615.9 million a year earlier (-45.1%). Source: the 10-K filed with the SEC on Mar 4, 2026. SEC
- What are Keros Therapeutics, Inc. (KROS)'s total liabilities?
- As of Dec 31, 2025, Keros Therapeutics, Inc. (KROS) reported total liabilities of $34.9 million, against $44.3 million a year earlier (-21.3%). Source: the 10-K filed with the SEC on Mar 4, 2026. SEC
- What are Keros Therapeutics, Inc. (KROS)'s cash and cash equivalents?
- As of Dec 31, 2025, Keros Therapeutics, Inc. (KROS) reported cash and cash equivalents of $287.4 million, against $559.9 million a year earlier (-48.7%). Source: the 10-K filed with the SEC on Mar 4, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:KROS&period_type=annual&limit=5"Information only, not investment advice.